New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
09:12 EDTPCS, ESIO, TOL, DTEGY, MTN, TEVA, BIG, S, PBY, GALE, DRIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Big Lots (BIG), up 7.3%... Toll Brothers (TOL), up 4.6%... ALSO HIGHER: Galena Biopharma (GALE), up 15% after signing NeuVax commercialization partnership with Teva (TEVA)... Electro Scientific (ESIO), up 12% after declaring $2/share special dividend... LOWER AFTER EARNINGS: Pep Boys (PBY), down 8.7%... Vail Resorts (MTN), down 7.3%... ALSO LOWER: Darden (DRI), down 8.9% after warning on Q2, FY13 EPS... MetroPCS (PCS), down 6.6% after Reuters says Sprint (S) unlikely to counter T-Mobile's (DTEGY) bid.
News For DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 27, 2015
05:40 EDTTEVATeva to acquire Allergan Generics for transaction valued at $40.5B
05:31 EDTTEVATeva reports Q2 non-GAAP operating income $1.6B
Subscribe for More Information
05:31 EDTTEVATeva raises FY15 EPS to $5.15-$5.40 from $5.05-$5.35, consensus $5.23
Subscribe for More Information
05:30 EDTTEVATeva reports Q2 non-GAAP EPS $1.43, consensus $1.31
Subscribe for More Information
05:28 EDTTEVATeva withdraws proposal to acquire Mylan
Teva (TEVA) announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan (MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Teva’s decision to terminate the proposal to acquire Mylan follows announcement that Teva has entered into a definitive agreement with Allergan (AGN) to acquire Allergan Generics. Teva CEO Erez Vigodman commented, “We continue to believe that a combination of Teva and Mylan would have made sense for our companies, our respective stockholders and the healthcare industry as a whole. However, despite our clear commitment to consummating a transaction, and our conviction that we ultimately would have succeeded in acquiring Mylan, we believe we have an even greater opportunity to create compelling, sustainable value for Teva’s stockholders through our transaction with Allergan – and we acted quickly to seize the opportunity. Our agreement with Allergan will reinforce Teva’s strategy to create an even stronger business model in the industry and will position us well to grow the business and better serve our customers and patients.” Teva intends to review its options with respect to its ownership of approximately 4.6% of the outstanding ordinary shares of common stock of Mylan.
July 26, 2015
18:22 EDTTEVAMedia reports say Teva to buy Allergan unit as it looks beyond Mylan
Subscribe for More Information
12:30 EDTTEVATeva nears deal to buy Allergan generics unit for $40.5B, Bloomberg says
Teva (TEVA) is nearing a deal to buy Allergan's (AGN) generic drug unit for roughly $40.5B and an agreement could be announced as early as Monday, reports Bloomberg, citing people familiar with the matter. Sources said Teva also plans to withdraw its bid for Mylan (MYL) as soon as Monday. Reference Link
12:17 EDTTEVATeva to cancel Mylan bid, plans offer for Allergan generics unit, Bloomberg says
Subscribe for More Information
July 24, 2015
11:59 EDTTEVALeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
06:56 EDTTEVAPaulson may play key role in Teva-Mylan-Perrigo drama, CTFN says
John Paulson's hedge fund, Paulson & Co., has upped its stake in Mylan (MYL) to 4.65%, which is below the threshold that would compel it to disclose its plans to the U.S. SEC but high enough for it to obtain standing before the Dutch Enterprise Chamber, which would hear any legal challenge to the "stichting" maneuver the company is employing to avoid a takeover by Teva (TEVA), said CTFN. The takeover fight is most likely headed for court in Amsterdam after Mylan's shareholder foundation exercised an option to acquire shares and Paulson's involvement is noteworthy since he teamed with Centaurus Capital in 2007 to thwart a stichting ploy used by Stork, the report noted. Reference Link
July 23, 2015
09:04 EDTTEVATeva says 'strongly disagrees' with Stichting stated analysis
Teva Pharmaceutical Industries (TEVA) issued the following statement regarding Stichting Preferred Shares Mylan’s (MYL) decision to exercise its call option: "We strongly disagree with the stated analysis of Stichting Preferred Shares Mylan and its decision to exercise its call option, which is unwarranted, relies on false assumptions, and risks depriving Mylan stockholders and other stakeholders of the value inherent in a combination of Teva and Mylan. We continue to believe that our proposed transaction offers a compelling opportunity for value-creation and many other benefits for the stockholders, customers, patients, and employees of both companies. We are well advised on Dutch law, including the ability of Mylan stockholders to challenge this action in court, and are prepared to take the necessary actions at the appropriate time."
08:48 EDTTEVAMylan, Teva lower after Stitching looks to thwart hostile deal
Subscribe for More Information
08:34 EDTTEVAMylan foundation exercises call option to 'level playing field'
08:33 EDTTEVAMylan foundation says shareholders at risk of Teva takeover
Subscribe for More Information
07:22 EDTSSprint price target lowered to $3 from $4 at Jefferies
Subscribe for More Information
06:57 EDTDRIDarden threatened with default call by bondholders over real estate, WSJ reports
Subscribe for More Information
July 22, 2015
10:06 EDTTEVAAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:30 EDTTEVAAbbott CEO says 'pretty alligned' with Mylan so far
July 21, 2015
20:08 EDTDTEGYSky criticizes 'highly damaging' proposal to merge BT Group, EE
Subscribe for More Information
July 20, 2015
10:26 EDTTEVALeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use